Ras-Related Protein Rab-32 and Thrombospondin 1 Confer Resistance to the EGFR Tyrosine Kinase Inhibitor Osimertinib by Activating Focal Adhesion Kinase in Non-Small Cell Lung Cance... von Kosibaty, Zeinab, Brustugun, Odd Terje, Zwicky Eide, Inger Johanne, Tsakonas, Georgios, Grundberg, Oscar, De Petris, Luigi, McGowan, Marc, Hydbring, Per, Ekman, Simon

Volltext

Real-World Data on EGFR and ALK Testing and TKI Usage in Norway-A Nation-Wide Population Study von Eide, Inger Johanne Zwicky, Nilssen, Yngvar, Stensland, Elin Marie, Brustugun, Odd Terje

Volltext

"Evaluation of ROS1 expression and rearrangements in a large cohort of early-stage lung cancer" von Dyrbekk, Anne Pernille Harlem, Warsame, Abdirashid Ali, Suhrke, Pål, Ludahl, Marianne Odnakk, Moe, Joakim Oliu, Eide, Inger Johanne Zwicky, Lund-Iversen, Marius, Brustugun, Odd Terje

Volltext

Epidemiology and outcome of peritoneal and pleural mesothelioma subtypes in Norway. A 20 year nation-wide study von Brustugun, Odd Terje, Nilssen, Yngvar, Eide, Inger Johanne Zwicky

Volltext

Using cell-free DNA to predict response to immunotherapy in non-small cell lung cancer pre- and post-treatment von Rao, Satyanarayan, Zukowski, Alexis, Weirich, Abigail, Kabos, Peter, Stensland, Elin Marie, Eide, Inger Johanne Zwicky, Brustugun, Odd Terje, Ramachandran, Srinivas

Volltext

Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study) von Eide, Inger Johanne Zwicky, Helland, Åslaug, Ekman, Simon, Mellemgaard, Anders, Hansen, Karin Holmskov, Cicenas, Saulius, Koivunen, Jussi, Grønberg, Bjørn Henning, Brustugun, Odd Terje

Volltext

Factors affecting outcome in resected EGFR-mutated lung cancer von Eide, Inger Johanne Zwicky, Nilssen, Yngvar, Lund-Iversen, Marius, Brustugun, Odd Terje

Volltext

Lung cancer treated abroad with receptor tyrosine kinase inhibitor von Eide, Inger Johanne Zwicky, Brustugun, Odd Terje

Volltext

Novel EGFR-directed therapy – a clinical study von Eide, Inger Johanne Zwicky

Volltext bestellen

Treatment beyond RECIST-defined progression in relapsed EGFR-mutated non-small cell lung cancer (NSCLC) patients treated with 2 nd line osimertinib von Eide, Inger Johanne Zwicky, Helland, Aslaug, Ekman, Simon, Cicenas, Saulius, Koivunen, Jussi, Grønberg, Bjørn Henning, Brustugun, Odd Terje

Volltext

Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study von Eide, Inger Johanne Zwicky, Grut, Harald, Helland, Åslaug, Ekman, Simon, Sørensen, Jens Benn, Hansen, Karin Holmskov, Grønberg, Bjørn Henning, Cicenas, Saulius, Koivunen, Jussi Pekka, Mellemgaard, Anders, Brustugun, Odd Terje

Volltext

Rapid drop in blood platelet count and increase in creatinine in non-small cell lung cancer (NSCLC) patients treated with osimertinib von Eide, Inger Johanne Zwicky, Helland, Aslaug, Ekman, Simon, Cicenas, Saulius, Koivunen, Jussi, Grønberg, Bjørn Henning, Brustugun, Odd Terje

Volltext

Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials von Eide, Inger Johanne Zwicky, Stensgaard, Simone, Helland, Åslaug, Ekman, Simon, Mellemgaard, Anders, Hansen, Karin Holmskov, Cicenas, Saulius, Koivunen, Jussi, Grønberg, Bjørn Henning, Sørensen, Boe Sandahl, Brustugun, Odd Terje

Volltext

Elevated expression of miR-494-3p is associated with resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer von Kaźmierczak, Dominika, Eide, Inger Johanne Zwicky, Gencheva, Radosveta, Lai, Yi, Lewensohn, Rolf, Tsakonas, Georgios, Grundberg, Oscar, de Petris, Luigi, McGowan, Marc, Brustugun, Odd Terje, Ekman, Simon, Hydbring, Per

Volltext

Lungekreft behandlet med reseptortyrosin=kinasehemmer i utlandet von Eide, Inger Johanne Zwicky, Brustugun, Odd Terje

Volltext

Plasma RNA profiling unveils transcriptional signatures associated with resistance to osimertinib in EGFR T790M positive non-small cell lung cancer patients von Alexeyenko, Andrey, Brustugun, Odd Terje, Eide, Inger Johanne Zwicky, Gencheva, Radosveta, Kosibaty, Zeinab, Lai, Yi, de Petris, Luigi, Tsakonas, Georgios, Grundberg, Oscar, Franzen, Bo, Viktorsson, Kristina, Lewensohn, Rolf, Hydbring, Per, Ekman, Simon

Volltext

Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials von Eide, Inger Johanne Zwicky, Stensgaard, Simone, Helland, Åslaug, Ekman, Simon, Mellemgaard, Anders, Hansen, Karin Holmskov, Cicenas, Saulius, Koivunen, Jussi, Grønberg, Bjørn Henning, Sørensen, Boe Sandahl, Brustugun, Odd Terje

Volltext

Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials von Eide, Inger Johanne Zwicky, Stensgaard, Simone, Helland, Åslaug, Ekman, Simon, Mellemgaard, Anders, Hansen, Karin Holmskov, Cicenas, Saulius, Koivunen, Jussi, Grønberg, Bjørn Henning, Sørensen, Boe Sandahl, Brustugun, Odd Terje

Volltext bestellen

Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study von Eide, Inger Johanne Zwicky, Grut, Harald, Helland, Åslaug, Ekman, Simon, Sørensen, Jens Benn, Hansen, Karin Holmskov, Grønberg, Bjørn Henning, Cicenas, Saulius, Koivunen, Jussi Pekka, Mellemgaard, Anders, Brustugun, Odd Terje

Volltext bestellen